| SC 13G/A | 2024-02-14 | CITADEL ADVISORS LLC | Decibel Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2023-09-27 | REGENERON PHARMACEUTICALS, INC. | Decibel Therapeutics, Inc. | 100 | 100.0% | EDGAR |
| SC 13D | 2023-08-18 | REGENERON PHARMACEUTICALS, INC. | Decibel Therapeutics, Inc. | 2,097,314 | 8.3% | EDGAR |
| SC 13G/A | 2023-02-14 | CITADEL ADVISORS LLC | Decibel Therapeutics, Inc. | - | 7.1% | EDGAR |
| SC 13G | 2023-02-03 | BlackRock Inc. | Decibel Therapeutics, Inc. | 1,805,108 | 7.2% | EDGAR |
| SC 13G/A | 2022-02-14 | CITADEL ADVISORS LLC | Decibel Therapeutics, Inc. | - | 7.1% | EDGAR |
| SC 13G | 2022-02-14 | GV 2016, L.P. | Decibel Therapeutics, Inc. | 321,978 | 1.3% | EDGAR |
| SC 13G | 2022-02-14 | Third Rock Ventures III, L.P. | Decibel Therapeutics, Inc. | 3,139,685 | 12.6% | EDGAR |
| SC 13G | 2022-02-11 | REGENERON PHARMACEUTICALS, INC. | Decibel Therapeutics, Inc. | 2,097,314 | 8.4% | EDGAR |
| SC 13D | 2021-03-02 | ORBIMED ADVISORS LLC | Decibel Therapeutics, Inc. | 4,061,774 | 16.7% | EDGAR |
| SC 13G | 2021-03-01 | CITADEL ADVISORS LLC | Decibel Therapeutics, Inc. | - | 7.4% | EDGAR |